# Clinical efficacy of upadacitinib in dermatological studies > Developing situation record from CLSTR: https://clstr.news/situations/clinical-efficacy-of-upadacitinib-in-dermatological-studies > Updated: 2026-10-20T02:25:42.000Z. Sources: 6. Developments: 2. Clinical research has highlighted the efficacy of the medication upadacitinib across different dermatological conditions. In studies regarding atopic dermatitis, data presented at the 2026 Fall Clinical Dermatology Conference indicated that dupilumab may reduce the risk of children developing subsequent allergic conditions, such as asthma or food allergies, by 33% to 52% compared to systemic corticosteroids. Furthermore, analysis of patients switching to upadacitinib after an inadequate response to dupilumab showed no skin lesion flares through 16 weeks. Separate phase 3 clinical trials published in JAMA Dermatology demonstrated that upadacitinib, a Janus kinase (JAK) inhibitor, can significantly restore hair in patients with severe alopecia areata. Results showed that between 13% and 22.5% of treated participants achieved complete hair regrowth after 24 weeks, with researchers noting improvements in patients' psychosocial well-being. ## Timeline ### 2026-10-20: Upadacitinib shows promise in treating severe alopecia areata Clinical trials published in JAMA Dermatology show that the JAK inhibitor upadacitinib can restore hair in patients with severe alopecia areata, with up to 22.5% achieving full regrowth. 4 sources. https://clstr.news/cluster/upadacitinib-shows-promise-in-treating-severe-alopecia-areata ### 2026-10-09: Dupilumab and upadacitinib show efficacy in atopic dermatitis studies Clinical studies show dupilumab reduces the risk of atopic march progression in children and that switching to upadacitinib can effectively manage atopic dermatitis without skin flares. 2 sources. https://clstr.news/cluster/dupilumab-and-upadacitinib-show-efficacy-in-atopic-dermatitis-studies --- Cite as: Clinical efficacy of upadacitinib in dermatological studies. CLSTR, https://clstr.news/situations/clinical-efficacy-of-upadacitinib-in-dermatological-studies